T.Man Pharmaceutical PCL Statistics

Total Valuation

T.Man Pharmaceutical PCL has a market cap or net worth of THB 5.60 billion. The enterprise value is 5.79 billion.

Market Cap	5.60B
Enterprise Value	5.79B

Important Dates

The next estimated earnings date is Friday, April 4, 2025.

Earnings Date	Apr 4, 2025
Ex-Dividend Date	n/a

Share Statistics

T.Man Pharmaceutical PCL has 400.00 million shares outstanding. The number of shares has increased by 18.78% in one year.

Current Share Class	n/a
Shares Outstanding	400.00M
Shares Change (YoY)	+18.78%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	27.00%
Owned by Institutions (%)	0.52%
Float	76.25M

Valuation Ratios

The trailing PE ratio is 10.25 and the forward PE ratio is 10.87.

PE Ratio	10.25
Forward PE	10.87
PS Ratio	2.02
PB Ratio	8.74
P/TBV Ratio	11.36
P/FCF Ratio	17.89
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.32, with an EV/FCF ratio of 18.50.

EV / Earnings	13.37
EV / Sales	2.64
EV / EBITDA	9.32
EV / EBIT	11.14
EV / FCF	18.50

Financial Position

The company has a current ratio of 0.66, with a Debt / Equity ratio of 0.56.

Current Ratio	0.66
Quick Ratio	0.36
Debt / Equity	0.56
Debt / EBITDA	0.48
Debt / FCF	0.95
Interest Coverage	41.22

Financial Efficiency

Return on equity (ROE) is 44.03% and return on invested capital (ROIC) is 22.88%.

Return on Equity (ROE)	44.03%
Return on Assets (ROA)	13.07%
Return on Capital (ROIC)	22.88%
Revenue Per Employee	2.33M
Profits Per Employee	458,988
Employee Count	944
Asset Turnover	0.88
Inventory Turnover	2.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	26.00
Average Volume (20 Days)	2,406,717

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, T.Man Pharmaceutical PCL had revenue of THB 2.20 billion and earned 433.28 million in profits. Earnings per share was 1.37.

Revenue	2.20B
Gross Profit	1.02B
Operating Income	519.71M
Pretax Income	507.10M
Net Income	433.28M
EBITDA	611.11M
EBIT	519.71M
Earnings Per Share (EPS)	1.37

Full Income Statement

Balance Sheet

The company has 105.50 million in cash and 297.26 million in debt, giving a net cash position of -191.76 million or -0.48 per share.

Cash & Cash Equivalents	105.50M
Total Debt	297.26M
Net Cash	-191.76M
Net Cash Per Share	-0.48
Equity (Book Value)	526.34M
Book Value Per Share	1.60
Working Capital	-633.72M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 514.03 million and capital expenditures -200.94 million, giving a free cash flow of 313.10 million.

Operating Cash Flow	514.03M
Capital Expenditures	-200.94M
Free Cash Flow	313.10M
FCF Per Share	0.78

Full Cash Flow Statement

Margins

Gross margin is 46.65%, with operating and profit margins of 23.66% and 19.73%.

Gross Margin	46.65%
Operating Margin	23.66%
Pretax Margin	23.09%
Profit Margin	19.73%
EBITDA Margin	27.82%
EBIT Margin	23.66%
FCF Margin	14.25%

Dividends & Yields

T.Man Pharmaceutical PCL does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	44.09%
Buyback Yield	-18.78%
Shareholder Yield	-18.78%
Earnings Yield	9.76%
FCF Yield	5.59%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

T.Man Pharmaceutical PCL has an Altman Z-Score of 1.4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.4
Piotroski F-Score	n/a